Literature DB >> 15862410

High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention.

Shigeto Namiuchi1, Yutaka Kagaya, Jun Ohta, Nobuyuki Shiba, Masafumi Sugi, Masayoshi Oikawa, Hiroyuki Kunii, Hidetsugu Yamao, Nobuo Komatsu, Mitsuru Yui, Hiroko Tada, Masahito Sakuma, Jun Watanabe, Toshikatsu Ichihara, Kunio Shirato.   

Abstract

OBJECTIVES: We investigated whether a higher serum erythropoietin (EPO) level in patients with acute myocardial infarction (MI) subjected to successful primary percutaneous coronary intervention (PCI) can predict a smaller infarct size determined by creatine kinase (CK) release.
BACKGROUND: Erythropoietin has been shown to protect cardiomyocytes from ischemia-reperfusion injury in rodents.
METHODS: We prospectively studied 101 patients with first MI who received successful primary PCI within 12 h from the onset of MI. Blood samples were collected to examine the serum EPO level after the primary PCI and within 24 h from the onset of MI.
RESULTS: The peak CK level and cumulative CK release were significantly lower in the above-median EPO group than in the below-median EPO group. Thrombolysis In Myocardial Infarction (TIMI) grades and collateral grades before PCI, infarct-related coronary arteries, time to the successful reperfusion from the onset of MI, and serum creatinine levels were similar in the two EPO groups. A stepwise multiple regression analysis revealed that the absolute serum EPO level (mU/ml) as well as TIMI grades after PCI and preinfarction angina was an independent predictor for the cumulative CK release.
CONCLUSIONS: These data suggest that a high endogenous EPO level can predict a smaller infarct size in patients with acute MI subjected to successful primary PCI. This might be attributed to the potentially protective effect of endogenous EPO against ischemia-reperfusion injury in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862410     DOI: 10.1016/j.jacc.2005.01.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.

Authors:  Jinling Hou; Shaohui Wang; Yan Chen Shang; Zhao Zhong Chong; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-08-01       Impact factor: 1.990

2.  Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats.

Authors:  Youngsook Lee; Arlo N McGinn; Curtis D Olsen; Kihoon Nam; Minhyung Lee; Sug Kyun Shin; Sung Wan Kim
Journal:  J Control Release       Date:  2013-06-25       Impact factor: 9.776

Review 3.  Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest.

Authors:  Raúl J Gazmuri; Jeejabai Radhakrishnan
Journal:  Crit Care Clin       Date:  2012-04       Impact factor: 3.598

4.  EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.

Authors:  Zhao Zhong Chong; Jinling Hou; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-05       Impact factor: 1.990

Review 5.  Erythropoietin: a future therapy for failing hearts?

Authors:  Lindsey Tilling; Brian Clapp
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

6.  Circulating levels of erythropoietin and its relation to arterial stiffness in patients with hypertension.

Authors:  Omer Gedikli; Abdulkadir Kiris; Caner Karahan
Journal:  Int J Clin Exp Med       Date:  2013-09-01

Review 7.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 8.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

Review 9.  Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.

Authors:  Haroon A Faraz; Syed F Zafar; Jalal K Ghali
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.